HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Nao Suzuki Selected Research

Clear Cell Adenocarcinoma

2/2010Transcription factor POU6F1 is important for proliferation of clear cell adenocarcinoma of the ovary and is a potential new molecular target.
11/2009POU6F1 is the transcription factor that might be involved in cell proliferation of clear cell adenocarcinoma of the ovary.
2/2009Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.
3/2008A synthetic retinoid, TAC-101 (4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid), plus cisplatin: potential new therapy for ovarian clear cell adenocarcinoma.
10/2007Biological and therapeutic significance of MUC1 with sialoglycans in clear cell adenocarcinoma of the ovary.
1/2006Expression of NEU3 (plasma membrane-associated sialidase) in clear cell adenocarcinoma of the ovary: its relationship with T factor of pTNM classification.
9/2005Loss of integrin alpha3 expression associated with acquisition of invasive potential by ovarian clear cell adenocarcinoma cells.
9/2004A novel retinoid, 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101), induces apoptosis of human ovarian carcinoma cells and shows potential as a new antitumor agent for clear cell adenocarcinoma.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Nao Suzuki Research Topics

Disease

45Neoplasms (Cancer)
05/2022 - 09/2004
18Ovarian Neoplasms (Ovarian Cancer)
01/2022 - 11/2004
12Carcinoma (Carcinomatosis)
01/2022 - 09/2004
8Clear Cell Adenocarcinoma
02/2010 - 09/2004
7Uterine Cervical Neoplasms (Cancer of the Cervix)
01/2022 - 06/2009
7Ovarian Epithelial Carcinoma
11/2021 - 09/2004
6Endometrial Neoplasms (Endometrial Cancer)
01/2022 - 10/2004
5Infertility (Sterility)
05/2021 - 10/2013
4Breast Neoplasms (Breast Cancer)
03/2021 - 06/2009
4Periodontitis
12/2020 - 01/2012
3Halitosis
01/2014 - 12/2008
3Body Weight (Weight, Body)
01/2010 - 01/2010
2Fallopian Tube Neoplasms
03/2021 - 06/2016
2Seizures (Absence Seizure)
08/2020 - 07/2008
2Squamous Cell Carcinoma (Epidermoid Carcinoma)
08/2017 - 03/2012
2Uterine Cervical Dysplasia
08/2017 - 03/2012
2Anorexia
01/2016 - 12/2013
2Neutropenia
01/2016 - 12/2009
2Diarrhea
01/2016 - 12/2009
2Arthralgia (Joint Pain)
01/2016 - 12/2013
2Nausea
01/2016 - 12/2013
2Hemorrhage
10/2013 - 08/2010
2Leukemia
07/2013 - 03/2009
2Tuberous Sclerosis (Bourneville's Disease)
03/2013 - 09/2012
2Epilepsy (Aura)
03/2013 - 09/2012
2Suppuration
03/2011 - 01/2009
2Periodontal Pocket (Periodontal Pockets)
08/2010 - 12/2008
2Adenocarcinoma
01/2006 - 10/2004
1B-Cell Lymphoma (Lymphoma, B Cell)
09/2022
1Leigh Disease (Leigh's Disease)
05/2022
1Placenta Accreta
01/2022
1Endometriosis
01/2022
1Primary Ovarian Insufficiency
01/2022
1Autoimmune Diseases (Autoimmune Disease)
09/2021
1Melanoma (Melanoma, Malignant)
07/2021
1Mobility Limitation (Difficulty Walking)
07/2021
1Ewing Sarcoma (Sarcoma, Ewing)
07/2021
1Triple Negative Breast Neoplasms
03/2021
1Residual Neoplasm
11/2020

Drug/Important Bio-Agent (IBA)

8Paclitaxel (Taxol)FDA LinkGeneric
03/2021 - 09/2004
8Cisplatin (Platino)FDA LinkGeneric
11/2020 - 09/2004
6Proteins (Proteins, Gene)FDA Link
08/2017 - 12/2006
4Messenger RNA (mRNA)IBA
09/2022 - 01/2006
4Pharmaceutical PreparationsIBA
05/2022 - 12/2006
4Carboplatin (JM8)FDA LinkGeneric
03/2021 - 03/2011
4Irinotecan (Camptosar)FDA LinkGeneric
11/2020 - 12/2009
4DNA (Deoxyribonucleic Acid)IBA
11/2018 - 09/2004
32- cyclohexylidenhydrazo- 4- phenyl- thiazoleIBA
11/2020 - 12/2009
3Sulfhydryl Compounds (Thiols)IBA
01/2018 - 12/2008
3Formaldehyde (Formol)FDA Link
08/2017 - 10/2007
3Polysaccharides (Glycans)IBA
08/2017 - 10/2007
3ParaffinIBA
08/2017 - 10/2007
3Biomarkers (Surrogate Marker)IBA
08/2017 - 06/2013
3Antineoplastic Agents (Antineoplastics)IBA
02/2010 - 09/2004
3Small Interfering RNA (siRNA)IBA
02/2010 - 02/2009
3Biological ProductsIBA
10/2007 - 09/2005
3Monoclonal AntibodiesIBA
10/2007 - 10/2004
2TubulinIBA
09/2022 - 02/2009
2Ceruloplasmin (Ferroxidase)IBA
01/2022 - 03/2014
2PlatinumIBA
11/2021 - 11/2020
2liposomal doxorubicin (Doxil)FDA Link
11/2021 - 03/2013
2EnzymesIBA
01/2018 - 09/2004
2Hydrogen Sulfide (Sulfide, Hydrogen)IBA
01/2018 - 10/2013
2LectinsIBA
08/2017 - 03/2014
2nedaplatinIBA
12/2013 - 06/2009
2trans-sodium crocetinate (crocetin)IBA
03/2013 - 09/2012
24-amino-4'-hydroxylaminodiphenylsulfone (HADS)IBA
08/2011 - 07/2011
2Transcription Factors (Transcription Factor)IBA
02/2010 - 11/2009
2taxaneIBA
12/2009 - 02/2009
2AcidsIBA
08/2009 - 09/2004
2RetinoidsIBA
03/2008 - 09/2004
2Benzoic Acid (Potassium Benzoate)FDA Link
03/2008 - 09/2004
2TAC 101IBA
03/2008 - 09/2004
2Immunoglobulin M (IgM)IBA
11/2004 - 10/2004
1Growth Differentiation Factor 9IBA
09/2022
1Lactic Acid (Lactate)FDA LinkGeneric
05/2022
1wisteria lectinIBA
01/2022
1NivolumabIBA
11/2021
11-dodecylpyridoxal (PLD)IBA
11/2021
1GemcitabineFDA Link
11/2021
1Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/2021
1Immune Checkpoint InhibitorsIBA
07/2021
1pembrolizumabIBA
07/2021
1AmmoniaIBA
12/2020

Therapy/Procedure

24Therapeutics
02/2022 - 10/2004
21Drug Therapy (Chemotherapy)
11/2021 - 02/2009
6Radiotherapy
07/2021 - 06/2009
3Aftercare (After-Treatment)
02/2022 - 06/2016
3Transplantation
01/2022 - 07/2013
3Cesarean Section (Caesarean Section)
01/2022 - 07/2020
3Hysterectomy
07/2021 - 06/2009
2Gynecologic Surgical Procedures (Gynecologic Surgery)
03/2021 - 11/2005
2Laparotomy
03/2021 - 03/2011
2Salpingo-oophorectomy
03/2021 - 03/2011
2Palliative Care (Palliative Therapy)
10/2016 - 06/2016
2Blood Transfusion (Blood Transfusions)
11/2010 - 11/2005
1Contraception (Birth Control)
05/2022
1Hemipelvectomy
07/2021
1Immunotherapy
07/2021
1Adjuvant Chemotherapy
03/2021